Anika Therapeutics, Inc. (ANIK) Guidance & Earnings Results
On 2026-07-29 Anika Therapeutics, Inc. raised guidance: "Adjusted EBITDA margin guidance raised to 13%-17% from prior; revenue guidance…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ANIKAnika Therapeutics, Inc.Follow ANIK — free
—
Price chart with a free account
- Market cap
- 286.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 29 Jul 26 | Raised | Adjusted EBITDA margin guidance raised to 13%-17% from prior; revenue guidance raised · full year |
| 8 Jan 26 | Reaffirmed | Revenue guidance reaffirmed: Commercial $47-$49.5M, OEM $62-$65M; Adj. EBITDA margin -3% to +3% · full year |
| 5 Nov 25 | Reaffirmed | Fiscal 2025 guidance reaffirmed · full year |
| 30 Jul 25 | Mixed | FY2025 revenue and EBITDA reaffirmed; Commercial Channel growth guidance for 2026-2027 revised to +10% to +20% from +20% to +30%; Hyalofast initial sales $3M in 2027. · full year |
Anika Therapeutics, Inc. — questions
- What guidance did Anika Therapeutics, Inc. give?
- On 2026-07-29: "Adjusted EBITDA margin guidance raised to 13%-17% from prior; revenue guidance raised"
- When does Anika Therapeutics, Inc. report earnings?
- Anika Therapeutics, Inc.'s next earnings report is expected on 2026-10-29.
Every figure on this page comes from Anika Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.